Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life (Q36445351)

14 August 2017

1 reference

title

Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life (English)

1 reference

14 August 2017

1 reference

Lodovico Balducci

1

1 reference

PubMed ID

16607649

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

14 August 2017

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

14 August 2017

106

1 reference

14 August 2017

2087-2094

1 reference

14 August 2017

10

1 reference

Infection in the myelodysplastic syndromes

14 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

Myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Myelodysplastic syndromes--coping with ineffective hematopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Blood transfusion from the recipient's perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Survival after transfusion as assessed in a large multistate US cohort.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Long-term survival after blood transfusion: a population based study in the North of England

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

The cost of allogeneic red blood cells--a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Remicade as TNF suppressor in patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21860

7 January 2021

Identifiers

DOI

10.1002/CNCR.21860

1 reference

14 August 2017

1 reference

PubMed ID

16607649